Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 4/20 | 0.41 |
| ▸ | ANPEP | P15144 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alafosfalin SCHEMBL1582303 | 1.00 | DPP4 (0.48) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL1582301 | 1.00 | DPP4 (0.48) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL11032329 | 1.00 | DPP4 (0.48) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL9619892 | 0.98 | DPP4 (0.47) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL11297483 | 0.98 | DPP4 (0.47) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL11299128 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL18919534 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL1582769 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL1582242 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL11296889 | 0.86 | PAX8 (0.40) | DPP4LAP3ANPEPDPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182950-B1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2017-07-19 | — | — | EP | claimed |
| EP-1945211-B1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | claimed |
| US-8759348-B2 | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2014-06-24 | — | — | US | claimed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | claimed |
| US-8207187-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-06-26 | — | — | US | claimed |
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-12-02 | — | — | US | claimed |
| EP-2182950-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2010-05-12 | — | — | EP | claimed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| WO-2008142384-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-11-27 | — | — | WO | claimed |
| EP-1945211-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2008-07-23 | — | — | EP | claimed |
| WO-2007054693-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| EP-0010067-A2 | Process for influencing plant growth | CIBA-GEIGY AG (CH) | 1980-04-16 | — | — | EP | claimed |
| EP-3607084-B1 | A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | UNIV WESTERN AUSTRALIA (AU) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023057598-A1 | METHODS INVOLVING BACTERIAL STRAIN REPLACEMENT | ELIGO BIOSCIENCE (FR) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057599-A1 | METHODS INVOLVING BACTEROIDES STRAIN REPLACEMENT | ELIGO BIOSCIENCE (FR) | 2023-04-13 | — | — | WO | disclosed |
| EP-2600868-B1 | COMBINATION OF A PYRROLOQUINOLINE COMPOUND AND AN AMINOGLYCODISE ANTIMICROBIAL AGENT | HELPERBY THERAPEUTICS LTD (GB) | 2022-03-09 | — | — | EP | disclosed |
| US-4331591-A | Chemical process for the production of α-aminophosphonic acids and peptide derivatives | CIBA-GEIGY CORPORATION (US) | 1982-05-25 | — | — | US | disclosed |
| US-4250085-A | PHOSPHONATE-CONTAINING OLIGOPEPTIDES, BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1981-02-10 | — | — | US | disclosed |
| EP-0010872-A1 | Process for producing alpha-aminophosphonic acids and their peptides and compounds thus obtained | CIBA-GEIGY AG (CH) | 1980-05-14 | — | — | EP | disclosed |
| EP-0010067-A2 | Process for influencing plant growth | CIBA-GEIGY AG (CH) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | ARG1, LPO, CTSL | DPP4 553/4885LAP3 571/4885ANPEP 1553/4885 |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | DPP4 1135/4885LAP3 612/4885ANPEP 1993/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | DPP4 1135/4885LAP3 612/4885ANPEP 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.